Cladribine in the treatment of hairy-cell leukaemia.
Cladribine, a purine nucleoside analogue, is a safe and effective treatment for patients with hairy-cell leukaemia. It is administered at a dose of 0.09 mg/kg daily as a continuous intravenous infusion over 7 days. This chapter discusses the history, rationale, chemical structure and mechanism of action of cladribine. The indications for therapy and guidelines for clinical usage are reviewed. The response of hairy-cell leukaemia to cladribine, the acute and chronic complications and the risk for second malignancies are summarized. The chapter concludes with a section on salvage therapy.
Goodman
Grant R
GR
Division of Hematology and Oncology, Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, CA 92037, USA.
Beutler
Ernest
E
Saven
Alan
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017338:Cladribine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006133:Growth Substances / Q000008:administration & dosage; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000378:metabolism; D015649:Pentostatin / Q000008:administration & dosage; D012074:Remission Induction; D016879:Salvage Therapy
D006133:Growth Substances; D016898:Interferon-alpha; D015649:Pentostatin; D017338:Cladribine